Comparison of treatment of hypokalemia with oral administration of potassium chloride vial or oral tablets

Introduction: Treatment of mild to moderate hypokalemia is a high potassium-containing diet and oral pharmaceutical potassium products. However, several medical centers in Iran use injectable dosage forms orally, which is not a confirmed method by reliable guidelines. Objectives: This study investig...

Full description

Saved in:
Bibliographic Details
Main Authors: Leila Sabetnia (Author), Farzaneh Hematian (Author), Hosein Jafari (Author), Reza Ganji (Author), Ahmad Nezhadisalami (Author)
Format: Book
Published: Society of Diabetic Nephropathy Prevention, 2024-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_edc31d51a74441a890e9c5348644e614
042 |a dc 
100 1 0 |a Leila Sabetnia  |e author 
700 1 0 |a Farzaneh Hematian  |e author 
700 1 0 |a Hosein Jafari  |e author 
700 1 0 |a Reza Ganji  |e author 
700 1 0 |a Ahmad Nezhadisalami  |e author 
245 0 0 |a Comparison of treatment of hypokalemia with oral administration of potassium chloride vial or oral tablets 
260 |b Society of Diabetic Nephropathy Prevention,   |c 2024-01-01T00:00:00Z. 
500 |a 2251-8363 
500 |a 2251-8819 
500 |a 10.34172/jnp.2023.21435 
520 |a Introduction: Treatment of mild to moderate hypokalemia is a high potassium-containing diet and oral pharmaceutical potassium products. However, several medical centers in Iran use injectable dosage forms orally, which is not a confirmed method by reliable guidelines. Objectives: This study investigated the advantages and side effects of oral tablets versus injection vials of potassium chloride orally. Patients and Methods: This descriptive-analytical cross-sectional study was performed from March 2022 to June 2022. Thirty patients received tablets ("potassium chloride tablet" group), and thirty patients received injection vials ("potassium chloride vials orally" group) of potassium chloride orally. The variables, including age, gender, clinical side effects, and serum level of potassium, were regularly recorded. Results: The mean duration of serum potassium normalization was 42.00 hours for the "potassium chloride tablet" group and 84.57 hours for the "potassium chloride vials orally" group. The mean total potassium intake was 127.20 mEq/L in the "potassium chloride tablet" group and 280.03 mEq/L for the "potassium chloride vials orally" group. No significant difference was observed in gastrointestinal complications, including esophagitis, bloating, stomach ache, and nausea. None of the patients have required endoscopy due to esophagitis. Conclusion: Our result suggested that prescribing oral potassium chloride tablets has superior benefits over injection vials. However, more detailed research is needed to reveal the other aspects of this problem. Study Registration: This study was retrospectively registered in Research Registry UIN (UIN: reviewregistry1668). 
546 |a EN 
690 |a hypokalemia 
690 |a potassium chloride 
690 |a oral potassium chloride 
690 |a potassium chloride vial 
690 |a Pathology 
690 |a RB1-214 
690 |a Internal medicine 
690 |a RC31-1245 
690 |a Other systems of medicine 
690 |a RZ201-999 
655 7 |a article  |2 local 
786 0 |n Journal of Nephropathology, Vol 13, Iss 1, Pp e21435-e21435 (2024) 
787 0 |n https://nephropathol.com/PDF/jnp-13-e21435.pdf 
787 0 |n https://doaj.org/toc/2251-8363 
787 0 |n https://doaj.org/toc/2251-8819 
856 4 1 |u https://doaj.org/article/edc31d51a74441a890e9c5348644e614  |z Connect to this object online.